Similar Papers

Paper Title
Journal
Date
Author
Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
Kelly S Chien ... Guillermo Garcia-Manero
Blood | VOL. 134
Kelly S Chien, et. al.Kelly S Chien ... Guillermo Garcia-Manero
13 Nov 2019
Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy
Kelly S Chien ... Guillermo Garcia-Manero
Blood | VOL. 136
Kelly S Chien, et. al.Kelly S Chien ... Guillermo Garcia-Manero
05 Nov 2020
Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
Kelly S Chien ... Guillermo Garcia-Manero
Blood | VOL. 136
Kelly S Chien, et. al.Kelly S Chien ... Guillermo Garcia-Manero
05 Nov 2020
Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study
Koji Sasaki ... Guillermo Garcia-Manero
Blood | VOL. 136
Koji Sasaki, et. al.Koji Sasaki ... Guillermo Garcia-Manero
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.